Boston Scientific (BSX) Asset Writedowns and Impairment (2010 - 2025)

Boston Scientific has disclosed Asset Writedowns and Impairment across 7 years of filings, most recently posting $51.0 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment fell 53.64% year-over-year to $51.0 million; the TTM figure through Dec 2025 stood at $188.0 million (up 69.37% YoY), while the FY2025 annual figure was $124.0 million, down 67.88% from the prior year.
• Asset Writedowns and Impairment came in at $51.0 million for Q4 2025 at Boston Scientific, up from $27.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $197.0 million in Q4 2021 to a low of $1.0 million in Q3 2023.
• Average Asset Writedowns and Impairment over 5 years is $85.5 million, with a median of $80.5 million recorded in 2024.
• Year-over-year, Asset Writedowns and Impairment surged 143.21% in 2021 and sank 99.2% in 2023.
• Over 5 years, Asset Writedowns and Impairment stood at $197.0 million in 2021, then sank by 36.55% to $125.0 million in 2022, then tumbled by 99.2% to $1.0 million in 2023, then surged by 10900.0% to $110.0 million in 2024, then tumbled by 53.64% to $51.0 million in 2025.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $51.0 million in Q4 2025, $27.0 million in Q3 2025, and $110.0 million in Q4 2024.